Calquence® (acalabrutinib) 100 mg Capsules for CLL/SLL and MCL

What Calquence Is and How It Works

Calquence® (acalabrutinib) is a Bruton tyrosine kinase (BTK) inhibitor used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). It is taken by mouth. The usual dosing schedule is twice daily. Many patients search for acalabrutinib without insurance to manage costs, and Calquence 100 mg is a common strength prescribed by oncologists.

YouDrugstore is a licensed Canadian pharmacy based in Manitoba. Prescriptions are reviewed by licensed pharmacists before dispensing. You can order online and reach our friendly customer-service chat during posted office hours.

We work with licensed, vetted partner pharmacies worldwide to source authentic brand medicines, with a broad selection and fair pricing. To learn more about this therapy, see our article Understanding Calquence Medication For Cancer Treatment.

Acalabrutinib blocks BTK signaling inside B cells. This helps slow or stop growth of the cancer cells. Calquence® may be used alone or with an anti-CD20 antibody, such as obinutuzumab, in CLL/SLL. It is often continued until disease progression or unacceptable toxicity.

Dosage and Usage

Follow the treatment plan from the prescriber. Strengths include 100 mg capsules and 100 mg tablets. The typical regimen is 100 mg every 12 hours. Food does not significantly change exposure. The capsule formulation should not be used with proton-pump inhibitors. The tablet formulation can be used with acid-reducing agents.

• Initiation: Many start at 100 mg twice daily.
• Titration: Dose holds or reductions may be used for side effects.
• Missed dose: If more than 3 hours late, skip and take the next dose at the regular time. Do not double up.
• Drug interactions: Avoid strong CYP3A inhibitors or inducers. If use is unavoidable, dose changes or monitoring may be required.
• Grapefruit/Seville oranges: Avoid due to CYP3A effects.

Storage and travel tips:

• Store at room temperature in the original bottle, tightly closed.
• Keep the desiccant in the bottle and protect from moisture.
• When you travel, carry the medicine in your hand luggage.
• Keep away from heat, humidity, and direct sunlight.
• Pack enough for your trip and a few extra days.

Benefits and Savings

Calquence® has shown high response rates in CLL/SLL, both in newly diagnosed and relapsed disease. In MCL, it can deliver rapid responses, especially in previously treated patients. Many people appreciate the oral route and the steady twice-daily cadence. Headache is common early and often improves over time.

Buying through Cancer treatment listings at YouDrugstore helps you access Canadian pricing. Typical savings are 60–80% compared with average US cash prices. We also support those paying without insurance by offering multi-month supply options at lower per-month costs.

For current promotions or bulk options, see our page for a calquence coupon.

Side Effects and Safety

Side effects can vary. Medical teams monitor closely and adjust therapy as needed.

• Very common: Headache, diarrhea, muscle aches, bruising, cough, fatigue.
• Hematologic: Low platelets, low neutrophils, and anemia may occur.
• Bleeding: From minor bruising to serious hemorrhage, especially with anticoagulants or antiplatelets.
• Infections: Bacterial, viral, or fungal, including pneumonia. Reactivation can occur in some viruses.
• Cardiac: Atrial fibrillation or flutter has been reported.
• Skin and other cancers: Non-melanoma skin cancers and other malignancies may occur over time. Sun protection is advised.
• Blood pressure: Hypertension can develop and may need management.
• Allergy: Hypersensitivity reactions are possible.

Pregnancy and breastfeeding: Acalabrutinib can harm an unborn baby. Effective contraception is required during treatment and for a period after the last dose. Breastfeeding is not recommended during treatment and for some time after the last dose.

Vaccines: Live vaccines should be avoided during treatment. Inactivated vaccines may be used after discussion with the care team.

Always review the full prescribing information and follow your oncology team’s guidance.

Onset Time

Some patients notice symptom relief within weeks. Lymph node size and blood counts may improve over one to three months. Early treatment can cause temporary lymphocytosis in CLL. This effect is expected with BTK inhibition and does not necessarily signal disease worsening. Deep responses can continue to build over many months.

Compare With Alternatives

Other BTK inhibitors include ibrutinib and zanubrutinib. Ibrutinib was the first-in-class agent and is taken once daily. Zanubrutinib is a newer option and may offer different tolerability for some patients. Choice depends on diagnosis, prior therapy, side-effect profile, drug interactions, and clinician preference.

Non-BTK options in CLL/SLL include venetoclax, often combined with obinutuzumab or rituximab for time-limited courses. Chemoimmunotherapy remains an option in selected cases. These are not direct substitutes for acalabrutinib, and selection is individualized.

Other targeted or immuno-oncology medicines available at our pharmacy include Bavencio®, Zytiga®, and Xospata®. These treat different cancers and are provided here for patients comparing oncology options.

Combination Therapy

In CLL/SLL, acalabrutinib may be used alone or with obinutuzumab. Combination regimens can offer deeper responses in some settings. For MCL, monotherapy is common after prior treatments. Concomitant anticoagulation and antiplatelet therapy increase bleeding risk. Warfarin is generally avoided with BTK inhibitors. Clinicians often coordinate timing around dental or surgical procedures to reduce bleeding risk. Acid-reducing agents interact differently by formulation: avoid proton-pump inhibitors with capsules; the tablet formulation can be taken with PPIs.

Patient Suitability and Cost-Saving Tips

Patients with a history of significant bleeding, recent surgery, or on blood thinners need careful risk assessment. Those with prior atrial fibrillation or uncontrolled hypertension may need closer monitoring. Strong CYP3A inhibitors or inducers can change exposure, so medication lists should be reviewed. Pregnancy, plans for pregnancy, or breastfeeding require discussion before therapy.

You can lower costs by choosing larger fills when appropriate. Reorder reminders help you avoid gaps in therapy. Pricing can be more manageable for acalabrutinib without insurance when you compare supply sizes and ask about bulk promotions.

If you want more background before starting therapy, read our guide Understanding Calquence Medication For Cancer Treatment. You can also browse our Cancer condition page for other therapies that your care team may consider at different times.

Authoritative Sources

See the manufacturer’s information on the AstraZeneca Calquence product page. Review regulatory details in the Health Canada Drug Product Database entry for acalabrutinib. You can also read the FDA Prescribing Information for Calquence.

YouDrugstore offers caring support, Canadian pricing, and pharmacist oversight from a licensed pharmacy. Order with confidence and receive prompt, express, cold-chain shipping when required.

This information is educational and not a substitute for professional medical advice. Always speak with your oncologist or pharmacist about your specific treatment.